Vantage logo

Finding the next Prevail

An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.

Vantage logo

Ash 2020 roundup

Evaluate Vantage's coverage of the virtual Ash 2020 congress.

Vantage logo

Ash 2020 – Crispr gets another boost

Data in three more patients support Crispr and Vertex’s hope of developing a functional cure for beta-thalassaemia and sickle cell disease.